• 1
    Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327: 10411044.
  • 2
    Webb AM, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ 1992;305: 927931.
  • 3
    WHO Task Force on Postovulatory Methods of Fertility RegulationComparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999;353: 697702.
  • 4
    Cheng L, Gulmezoglu AM, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database of Systematic Reviews 2000: CD001324.
  • 5
    Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU486). Hum Reprod 1992;7: 945950.
  • 6
    Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J Clin Endocrinol Metabol 1987;65: 11351140.
  • 7
    Baird DT, Glasier AF. Drug therapy: hormonal contraception. N Engl J Med 1993;328: 15431549.
  • 8
    Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993;45: 384409.
  • 9
    Gemzell-Danielsson K, Svalander P, Swahn ML, Johannisson E, Bygdeman M. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase. Hum Reprod 1994;9: 23982404.
  • 10
    WHO Task Force on Postovulatory Methods of Fertility RegulationRandomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352: 428433.
  • 11
    Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995;333: 15171521.
  • 12
    Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 1978;62: 10371040.
  • 13
    SPSS Inc. Reference Guide, Version 7.5. Chicago, Illinois, USA, 1997.
  • 14
    Royal Pharmaceutical Society of Great Britain. British National Formulary. Bath: British Medical Association, The Bath Press, 1995.
  • 15
    Ashok PW, Wagaarachchi PT, Flett GM, Templeton A. Mifepristone as a late post-coital contraceptive. Hum Reprod 2001;16: 7275.
  • 16
    Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998;57: 363369.
  • 17
    Alan Guttmacher Institute. Sharing Responsibility: Women, Society, and Abortion Worldwide. New York, 1999.
  • 18
    World Health Organization. Unsafe abortion (WHD 98.10). World Health Day/Safe Motherhood: 7 April 1998 (Address).
  • 19
    World Health Organization. A Tabulation of Available Data on the Frequency and Mortality of Unsafe Abortion. Geneva : WHO, 1997.